1.21
price down icon3.20%   -0.04
after-market Dopo l'orario di chiusura: 1.22 0.01 +0.83%
loading
Precedente Chiudi:
$1.25
Aprire:
$1.25
Volume 24 ore:
166.40K
Relative Volume:
0.34
Capitalizzazione di mercato:
$55.31M
Reddito:
-
Utile/perdita netta:
$-40.56M
Rapporto P/E:
-1.0342
EPS:
-1.17
Flusso di cassa netto:
$-35.28M
1 W Prestazione:
+0.83%
1M Prestazione:
-24.38%
6M Prestazione:
-21.94%
1 anno Prestazione:
-67.86%
Intervallo 1D:
Value
$1.20
$1.2691
Intervallo di 1 settimana:
Value
$1.12
$1.2691
Portata 52W:
Value
$0.8505
$4.29

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Name
Nome
Pds Biotechnology Corporation
Name
Telefono
800-208-3343
Name
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Name
Dipendente
24
Name
Cinguettio
@pdsbiotech
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
PDSB's Discussions on Twitter

Confronta PDSB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PDSB
Pds Biotechnology Corporation
1.21 52.57M 0 -40.56M -35.28M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-11-01 Iniziato B. Riley Securities Buy
2021-06-28 Iniziato Cantor Fitzgerald Overweight
2020-11-10 Aggiornamento H.C. Wainwright Neutral → Buy
2020-05-27 Iniziato Alliance Global Partners Buy
2020-03-09 Iniziato Noble Capital Markets Outperform
2019-10-24 Iniziato Chardan Capital Markets Buy
Mostra tutto

Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie

pulisher
Jul 24, 2025

Is PDS Biotechnology Corporation stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

PDS Biotechnology Corporation Stock Analysis and ForecastDynamic profit expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about PDS Biotechnology Corporation stockMarket-crushing stock picks - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

What drives PDS Biotechnology Corporation stock priceFree Stock Movement Tracking - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How PDS Biotechnology Corporation stock performs during market volatilityHigh Yield Stock Selection - Newser

Jul 22, 2025
pulisher
Jul 20, 2025

Is PDS Biotechnology Corporation a good long term investmentSuperior capital gains - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 15, 2025

Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Stock Market Knowledge Sharing - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes PDS Biotechnology Corporation stock price move sharplyFree Access to Investment Community - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

PDS Biotechnology completes recruitment for stage one of colorectal cancer trial - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotechnology stock rises after trial meets criteria for expansion By Investing.com - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotechnology stock rises after trial meets criteria for expansion - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotech's PDS01ADC: A Breakthrough in Cytokine Therapy for Metastatic Colorectal Cancer - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - The Manila Times

Jul 10, 2025
pulisher
Jul 10, 2025

PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results - Stock Titan

Jul 10, 2025
pulisher
Jul 01, 2025

PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 18, 2025

PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

Jun 18, 2025
pulisher
Jun 17, 2025

Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

PDS Biotechnology holds a conference call - TipRanks

Jun 17, 2025
pulisher
Jun 14, 2025

PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World

Jun 14, 2025
pulisher
Jun 14, 2025

HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

PDS Biotech expands equity incentive plan - Investing.com

Jun 11, 2025

Pds Biotechnology Corporation Azioni (PDSB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):